Laman UtamaLSTA • NASDAQ
add
Lisata Therapeutics Inc
Tutup sebelumnya
$2.82
Julat hari
$2.86 - $2.94
Julat tahun
$2.05 - $3.83
Permodalan pasaran
23.99J USD
Bilangan Purata
15.39K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 5.34J | -10.53% |
Pendapatan bersih | -4.93J | 6.29% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -0.59 | 9.23% |
EBITDA | -5.29J | 10.53% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 35.86J | -34.08% |
Jumlah aset | 38.20J | -34.24% |
Jumlah liabiliti | 4.76J | -11.55% |
Jumlah ekuiti | 33.44J | — |
Syer tertunggak | 8.39J | — |
Harga kepada buku | 0.70 | — |
Pulangan pada aset | -33.03% | — |
Pulangan pada modal | -37.23% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Sep 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -4.93J | 6.29% |
Tunai daripada operasi | -2.52J | 29.72% |
Tunai daripada pelaburan | -6.30J | -151.46% |
Tunai daripada pembiayaan | 0.00 | 100.00% |
Perubahan bersih dalam tunai | -8.78J | -200.53% |
Aliran tunai bebas | -1.00J | 39.01% |
Perihal
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through the acquisition of Cend Therapeutics by Caladrius Biosciences in September 2022.
In April 2024 the FDA granted their product, certepetide, orphan drug status. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Diasaskan
1980
Ibu pejabat
Tapak web
Pekerja
25
